The interaction at MET793 within EGFR's ATP‐binding pocket suggests that ZAK‐I‐57 may function as a non‐ATP‐competitive inhibitor, a crucial distinction that reduces the likelihood of resistance mutations, a limitation seen with erlotinib‐resistant HCC case [60]. Here, EGFR is linked to hepatocellular carcinoma.